NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Feb 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
4/8 — Partial
OXYTROL (oxybutynin) by AbbVie is cholinergic muscarinic antagonists [moa]. First approved in 2003.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXYTROL (oxybutynin) is a transdermal, extended-release small-molecule cholinergic muscarinic antagonist approved in 2003 for overactive bladder and related urinary disorders. It works by blocking acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and urinary urgency. The product is indicated for overactive bladder, neurogenic bladder, urge urinary incontinence, urinary frequency, and emerging uses in hot flashes and cognition.
$2MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Medicare claims, indicating shrinking addressable market and likely reduced team investment.
Mechanism of Action
Cholinergic Muscarinic Antagonists
Pharmacologic Class:
Cholinergic Muscarinic Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (14)
Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction
Started Jan 2026
60 enrolled
Spina Bifida
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
Started Oct 2021
88 enrolled
Prostate Carcinoma
Oxybutynin Chloride in Managing Hot Flashes
Started Dec 2016
150 enrolled
Breast CarcinomaDuctal Breast Carcinoma In SituHot Flashes+2 more
A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment
Started Aug 2016
47 enrolled
Overactive BladderMild Cognitive Impairment
A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults
Started Feb 2016
10 enrolled
Hyperhidrosis
Worked on OXYTROL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.